BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 24362817)

  • 1. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.
    Piotrowski A; Xie J; Liu YF; Poplawski AB; Gomes AR; Madanecki P; Fu C; Crowley MR; Crossman DK; Armstrong L; Babovic-Vuksanovic D; Bergner A; Blakeley JO; Blumenthal AL; Daniels MS; Feit H; Gardner K; Hurst S; Kobelka C; Lee C; Nagy R; Rauen KA; Slopis JM; Suwannarat P; Westman JA; Zanko A; Korf BR; Messiaen LM
    Nat Genet; 2014 Feb; 46(2):182-7. PubMed ID: 24362817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.
    van den Munckhof P; Christiaans I; Kenter SB; Baas F; Hulsebos TJ
    Neurogenetics; 2012 Feb; 13(1):1-7. PubMed ID: 22038540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
    Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
    Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.
    Sestini R; Bacci C; Provenzano A; Genuardi M; Papi L
    Hum Mutat; 2008 Feb; 29(2):227-31. PubMed ID: 18072270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
    Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
    Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.
    Hutter S; Piro RM; Reuss DE; Hovestadt V; Sahm F; Farschtschi S; Kehrer-Sawatzki H; Wolf S; Lichter P; von Deimling A; Schuhmann MU; Pfister SM; Jones DT; Mautner VF
    Acta Neuropathol; 2014 Sep; 128(3):449-52. PubMed ID: 25008767
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
    Smith MJ; Isidor B; Beetz C; Williams SG; Bhaskar SS; Richer W; O'Sullivan J; Anderson B; Daly SB; Urquhart JE; Fryer A; Rustad CF; Mills SJ; Samii A; du Plessis D; Halliday D; Barbarot S; Bourdeaut F; Newman WG; Evans DG
    Neurology; 2015 Jan; 84(2):141-7. PubMed ID: 25480913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
    Kehrer-Sawatzki H; Farschtschi S; Mautner VF; Cooper DN
    Hum Genet; 2017 Feb; 136(2):129-148. PubMed ID: 27921248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistence of schwannomatosis and glioblastoma in two families.
    Deiller C; Van-Gils J; Zordan C; Tinat J; Loiseau H; Fabre T; Delleci C; Cohen J; Vidaud M; Parfait B; Goizet C
    Eur J Med Genet; 2019 Aug; 62(8):103680. PubMed ID: 31128261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of SMARCB1 expression in respectively schwannoma and renal tumor cells.
    Hulsebos TJ; Kenter S; Baas F; Nannenberg EA; Bleeker FE; van Minkelen R; van den Ouweland AM; Wesseling P; Flucke U
    Genes Chromosomes Cancer; 2016 Apr; 55(4):350-4. PubMed ID: 26799435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis.
    Hulsebos TJ; Kenter SB; Jakobs ME; Baas F; Chong B; Delatycki MB
    Clin Genet; 2010 Jan; 77(1):86-91. PubMed ID: 19912265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutation of INI1/SMARCB1 in familial schwannomatosis.
    Hulsebos TJ; Plomp AS; Wolterman RA; Robanus-Maandag EC; Baas F; Wesseling P
    Am J Hum Genet; 2007 Apr; 80(4):805-10. PubMed ID: 17357086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.
    Hadfield KD; Newman WG; Bowers NL; Wallace A; Bolger C; Colley A; McCann E; Trump D; Prescott T; Evans DG
    J Med Genet; 2008 Jun; 45(6):332-9. PubMed ID: 18285426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.
    Christiaans I; Kenter SB; Brink HC; van Os TA; Baas F; van den Munckhof P; Kidd AM; Hulsebos TJ
    J Med Genet; 2011 Feb; 48(2):93-7. PubMed ID: 20930055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis.
    Hulsebos TJ; Kenter S; Siebers-Renelt U; Hans V; Wesseling P; Flucke U
    Am J Surg Pathol; 2014 Mar; 38(3):421-5. PubMed ID: 24525513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.
    Rousseau G; Noguchi T; Bourdon V; Sobol H; Olschwang S
    BMC Neurol; 2011 Jan; 11():9. PubMed ID: 21255467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
    Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
    BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
    Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
    J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.